Equity (Details) $ / shares in Units, dose in Millions, $ in Millions		1 Months Ended		3 Months Ended
	Mar. 18, 2021 USD ($)	Feb. 28, 2022 USD ($) $ / shares shares	Feb. 28, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2022 dose $ / shares shares	Dec. 31, 2021 $ / shares shares	Mar. 01, 2021 dose $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share) | $ / shares					$ 0.01	$ 0.01
Purchase Obligation		$ 14.3
Common stock, shares authorized (in shares) | shares					295,000,000	295,000,000
Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Preferred stock, outstanding				$ 5.0
Series B Warrants | Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input				0.15
COVAXIN Preferred Stock Purchase Agreement | Series B Warrants
Subsidiary, Sale of Stock [Line Items]
Agreement to sell, number of shares issued in transaction (in shares) | shares							100,000
Convertible preferred stock, par value (in USD per share) | $ / shares							$ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares							$ 109.60
Sale Of Stock, Agreement To Sell, Advance Payment Amount	$ 6.0
Convertible preferred stock, shares issued upon conversion (in shares) | shares							10
Supply agreement, number of doses | dose					10.0		10.0
Public Offering Of Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares		16,000,000
Price per share (in USD per share) | $ / shares		$ 3.13
Proceeds from sale of stock		$ 49.8
Registered Direct Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares			3,000,000
Price per share (in USD per share) | $ / shares			$ 7.65
Proceeds from sale of stock			$ 21.2
Commissions, fees and expenses			$ 1.7
ATMs
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold | shares				1,000,000
Proceeds from sale of stock				$ 4.8
Commissions, fees and expenses				$ 0.1